Home  |  Site Map  |  Contact Us  |  


Corporate Profile

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.  XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis.  Regnite is being marketed in Japan by Astellas Pharma Inc.  XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

PDF XenoPort Investor Presentation; March 2015    1.4 MB Add to Briefcase

Stock Information


$7.29 + 0.02
Jul 28, 2015 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph